CTXR Citius Pharmaceuticals Inc
Company Analysis
Latest News
🟢 Citius Pharmaceuticals is trading 7.1% up today after accelerating LYMPHIR commercial adoption
Citius Pharmaceuticals is trading 7.1% up at $0.69 after Citius Oncology reported accelerating LYMPHIR commercial adoption. - New ordering institutions rose...
Citius Pharma's Cancer Drug Is Gaining Traction Fast — But Can Sales Outrun a Cash Crisis?
Shares of Citius Pharmaceuticals surged 10.4% to $0.69 after its oncology subsidiary disclosed that its sole commercial product — a targeted therapy for a rare...
🔴 Citius Pharmaceuticals is trading 11.49% down today as investors lock in LYMPHIR rally gains
Citius Pharmaceuticals is trading 11.49% down at $0.69 after profit-taking and consolidation following the LYMPHIR-driven rally. - Shares rose 25.45% to $0.78...
🔴 Citius Pharmaceuticals is trading 7.5% down today on profit-taking after LYMPHIR rally
Citius Pharmaceuticals is trading 7.5% down now at $0.72 after profit-taking and consolidation following a sharp LYMPHIR-driven rally. - Shares gained 25.45%...
🔴 Citius Pharmaceuticals is trading 6.5% down today after a sharp LYMPHIR-driven rally
Citius Pharmaceuticals is trading at $0.73 (-6.5%) in pre-market action, easing after a significant multi-day rally. • The stock is experiencing profit-taking...
🔴 Citius Pharmaceuticals is trading 5.2% down today on profit-taking after a sharp post-LYMPHIR rally
Citius Pharmaceuticals is trading at $0.74 (5.2% down) in after-hours trading, easing back after a strong multi-day rally driven by positive commercial...
🟢 Citius Pharmaceuticals is trading 10.4% up today after reporting 78% growth in new LYMPHIR accounts
Citius Pharmaceuticals is trading at $0.69 (+10.39%) after reporting significant commercial momentum for LYMPHIR through its oncology subsidiary. • The...
Citius Reports 78% Quarterly Growth in New Accounts for Cancer Drug LYMPHIR
Citius Pharmaceuticals' subsidiary, Citius Oncology, announced strong commercial momentum for its cancer treatment LYMPHIR®, which is used for cutaneous T-cell...
🟢 Citius Pharmaceuticals is trading 8% up today as it extends its recent rebound amid broader risk-on sentiment
Citius Pharmaceuticals is trading at $0.67 (8% up) as it extends its recent rebound, likely driven by broader risk-on sentiment and the ongoing LYMPHIR launch...
🟢 Citius Pharmaceuticals is trading 5.1% up today amid a broader market rally
Citius Pharmaceuticals is trading 5.1% up today at $0.63, extending its rebound as major U.S. indices rally more than 1.5%. • The stock continues to recover...
🟢 Citius Pharmaceuticals is trading 5.3% up today, rebounding from post-LYMPHIR profit-taking
Citius Pharmaceuticals is trading 5.3% up at $0.60, rebounding after last week’s profit-taking drop tied to the LYMPHIR commercialization rally. • The move...
🔴 Citius Pharmaceuticals is trading 10% down today as traders take profits after LYMPHIR rally
Citius Pharmaceuticals is trading approximately 10% down at $0.57 as traders take profits following a sharp multi-day rally tied to LYMPHIR’s commercialization...
🔴 Citius Pharmaceuticals is trading 6% down today as investors lock in profits after a multi-day LYMPHIR rally driven by expanding commercialization
• Citius Oncology announced nationwide deployment of LYMPHIR's broadened commercial organization and expanding market adoption on July 21, 2026. • This...
🟢 Citius Pharmaceuticals is trading 9.2% up today as multi-day rally extends on LYMPHIR oncology progress
Citius Pharmaceuticals is trading at $0.69 (+9.2%) in pre-market, extending a sharp multi-day rally. The momentum follows strong investor reaction to fiscal Q2...
Citius Pharma Rides a 26% Two-Day Rally on Its Cancer Drug Launch — But Can $5.6 Million in Revenue Justify the Momentum?
Shares of Citius Pharmaceuticals surged 10.4% to $0.63 on July 30, extending a sharp two-day rally from $0.50 without any fresh company-specific headline. The...
🟢 Citius Pharmaceuticals is trading 10.3% up today, extending a two-day rally following its recent earnings report
Citius Pharmaceuticals is trading 10.3% up today at $0.63, extending a sharp two-day rally from $0.50 as momentum continues to build. • The upward move...
🟢 Citius Pharmaceuticals is trading 8.8% up today, extending momentum from yesterday's double-digit gain
Citius Pharmaceuticals is trading at $0.62 (up 8.8%), extending momentum from yesterday's 14.3% regular-session gain to $0.57. • The move occurs without any...
🔴 Citius Pharmaceuticals is trading 6.5% down today on profit-taking after a sharp regular-session rally
Citius Pharmaceuticals is trading at $0.53 (6.5% down) in after-hours trading as investors lock in profits following a significant rally during the regular...
🟢 Citius Pharmaceuticals is trading 10.2% up today as it rebounds from recent weakness amid healthcare sector strength
Citius Pharmaceuticals is trading 10.2% up today at $0.55, rebounding from recent weakness in the small-cap biotech space and previous dilution concerns. •...
🔴 Citius Pharmaceuticals is trading 5.3% down today amid small-cap biotech pressure and dilution concerns
Citius Pharmaceuticals is trading at $0.49 (-5.28%) after sliding from its prior close near $0.52, with no new company-specific announcements to explain the...